<DOC>
	<DOCNO>NCT01507610</DOCNO>
	<brief_summary>The purpose study : - To compare single-dose pharmacokinetics ( PK ) intranasal administration 20 mg OPTINOSE SUMATRIPTAN 20 mg IMITREX® ( sumatriptan ) Nasal Spray , 100 mg IMITREX® ( sumatriptan ) Oral Tablet , 6 mg IMITREX® ( sumatriptan ) Subcutaneous Injection , healthy subject . - To estimate relative bioavailability single-dose intranasal administration 20 mg OPTINOSE SUMATRIPTAN , 20 mg IMITREX® ( sumatriptan ) Nasal Spray , 100 mg IMITREX® ( sumatriptan ) Oral Tablet compare single-dose 6 mg IMITREX® ( sumatriptan ) Subcutaneous Injection , healthy subject .</brief_summary>
	<brief_title>Bioavailability Study Compare OPTINOSE SUMATRIPTAN With IMITREX® Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Men woman age 18 55 year , inclusive , screen . Healthy clinically relevant abnormality opinion Investigator determine medical history , physical examination , blood chemistry , hematology , include complete blood count , urinalysis , vital sign , ECG . Have BMI 1832 kg/m2 , inclusive , body weight less 50 kg . For female childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : intrauterine device place least 3 month prior first dose throughout study . barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study . surgical sterilization partner ( vasectomy 6 month minimum ) . hormonal contraceptive least 3 month prior first dose study throughout study . Female subject claim sexually inactive , become sexually active course study must agree use barrier method ( e.g . condom , diaphragm ) spermicide time start sexual activity completion study . In addition , female subject childbearing potential advise remain sexually inactive keep birth control method whole duration study . Females nonchildbearing potential must undergo one follow sterilization procedure least 6 month prior Day 1 : bilateral tubal ligation hysterectomy bilateral oophorectomy postmenopausal amenorrhea least 1 year prior Day 1 follicle stimulate hormone ( FSH ) serum level ≥ 40 mIU/mL . Women childbearing potential must negative serum betahuman chorionic gonadotropin screen visit checkin prior dose . Agree abstain alcohol intake 48 hour administration study agent inpatient portion study . Agree limit caffeine/methylxanthine ( eg , coffee , tea , chocolate , caffeinecontaining soft drink ) intake less 300 mg/day 7 day prior duration study ( 300 mg caffeine equal approximately 3 cup coffee 6 cola drink ) , intake 24 hour dose throughout confinement . Agree consume food beverage contain , grapefruit grapefruit juice , Seville oranges , quinine ( e.g . tonic water ) 72 hour prior study Day 1 last PK sample collect . Agree consume food contain poppy seed study . Have verify airflow nostril ability close soft palate . Must able use OptiNose device correctly . Subjects must understand English sign informed consent document indicate understand purpose procedure require study willing participate study . Be willing adhere study visit schedule protocol requirement . Currently history disease dysfunction pulmonary , cardiovascular , endocrine , hematologic , neurological , immune , gastrointestinal , genitourinary , body system clinically significant opinion Investigator . Have evidence chronic medical condition require prescription medication ( eg , hypertension diabetes ) . Have history migraine . History hypersensitivity allergy drug compound , include sumatriptan , component sulphonamides . Have major traumatic surgery within 12 week prior screen , preplanned surgery procedure would interfere conduct study . Have acute illness within 7 day prior study agent administration major illness hospitalization within 1 month prior study agent administration . Have clinically significant finding screen ECG . Have recent history ( within 1 previous year ) alcohol drug abuse . History smoking use nicotinecontaining substance within previous 2 month . Have abnormal value hematology , clinical chemistry , urinalysis screen checkin consider clinically significant Investigator . Have positive serology test HIV antibody , HBsAg , hepatitis C virus antibody ( antiHCV ) screening . Have positive urine drug screen ethanol substance abuse include cocaine , cannabinoids , phencyclidine , amphetamine , benzodiazepine , barbiturate , opiate , propoxyphene , methadone screening checkin . Have haemoglobin level lower limit normal screening . Have donate blood experience significant blood loss ( volume &gt; 500 mL ) within 3 month prior screen , plan donate within 2 month completion study . Use drug metabolize enzyme ( CYP450 ) inducer within 28 day prior dose inhibitor within 14 day prior dose ( refer Appendix 1 ) . Use monoamine oxidase inhibitor ( MAOI ) within 28 day prior dose . Use prescription medications/products , except hormonal contraceptive , within 14 day prior study entry . Use OTC , nonprescription preparation ( include mineral phytotherapeutic/herbal/plantderived preparation ) , within 14 day prior study entry , exception ibuprofen , acetaminophen use recommended dos . For acetaminophen , maximum 1500 mg per day 3 g per week , allow treatment headache pain . Participation investigational study drug trial receipt investigational study drug occur within 4 week prior dose , plan participate investigational drug study le 1 month completion study . A recent febrile illness within 3 day start study drug intake Day 1 . If woman , must breastfeed plan become pregnant study . Must refrain physical activity ( jogging , strenuous exercise type ) , sunbathe confine study center 48 hour admission study center . Reports exhibit abnormality regard sense smell and/or taste . Reports temporary loss abnormality sense smell and/or taste due recent ( within 2 week prior Day 1 ) cold viral infection . Presence respiratory disease know nasal obstruction include allergic rhinitis , nasal septum deviation , polyposis , severe mucosal swell , nasal ulcer , nasal trauma , reason . Have history chronic nose bleeds . Current nasopharyngeal illness . Known velum insufficiency , ie , cleft palate and/or structural abnormality soft palate nasopharynx . Any condition opinion Investigator would complicate compromise study , wellbeing subject . Is employee Investigator/study center Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>sumatriptan</keyword>
	<keyword>bioavailability</keyword>
</DOC>